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Background/aim: The aim of this study was to determine the presence and age distribution of different oncogenic human papilloma
virus (HPV) types in women in the South Backa region and its relationship to Pap results.
Materials and methods: In a group of 1087 women with normal and abnormal cytology, the commercial HR HPV Real-TM kit (Sacace
Biotechnologies, Italy) was used.
Results: Overall, 50.5% of the women were HPV positive. The presence of HPV types 18, 31, 51, and 58 was significantly influenced by
age, while the presence of HPV types 16 and 45 was significantly influenced by cervical cytology. Results of the LSD test show a wide
spectrum of high risk HPV among women with normal cytology and women with a low grade cervical lesion rate (atypical squamous
cell of undetermined significance (ASCUS) and low grade squamous intraepithelial lesions (LSIL). The most prevalent HPV types found
were 16, 31, 51, 18, and 52. In the HSIL group the most prevalent HPV types were 16 and 45.
Conclusion: The reported results provide new data on the circulation of oncogenic HPV genotypes and frequency of multiple infections
among women in Vojvodina and suggest that a prophylactic vaccine against HPV 16 and 18 has the potential to prevent approximately
half of the high-grade lesions.
Key words: Human papilloma virus, real-time PCR, cervical cytology

1. Introduction
Cervical cancer is the fourth most common cancer in
women, and the seventh overall, with an estimated 528,000
new cases and 266,000 deaths worldwide in 2012. More
than 88% of the deaths occur in low-income countries and
that percentage is predicted to reach 91.5% by 2030. (1).
According to the latest data from GLOBOCAN study, the
incidence of cervical cancer in Serbia is 23.8 per 100,000
and among the European countries it is ranked fourth,
after Romania, Lithuania, and Bulgaria. Currently, with
1501 new cases and approximately 609 deaths per year,
cervical cancer is the fifth cause of death from cancer
among Serbian women. The values of the incidence rate
of cervical cancer in Serbia are still among the highest and
approximately twice the average incidence rate in Europe
(11.2 to 100,000) (2). Furthermore, cervical cancer is the
second most common female cancer in women aged 15 to
44 years in Serbia (3).
* Correspondence: gordana.kovacevic@izjzv.org.rs

It is well known that human papilloma virus (HPV)
infection plays a major role in the development of cervical
cancer. HPV carcinogenicity has been convincingly
established for cervical cancer and it is generally accepted
that HPV infection is a necessary prerequisite for the
development of invasive cervical cancer (ICC). More
than 40 types of HPV can infect the anogenital tract (4).
The most common types of HPV that can be found in
cancers belong to phylogenetically different branches of
the genus Alpha. The International Agency for Research
on Cancer has classified HPV 16 and 18 as human cervical
carcinogens since 1995 (5). By 2011 the group was
expanded to include HPV 31, 33, 35, 39, 45, 51, 52, 56, 58,
and 59 (6). It is estimated that over 50%–80% of sexually
active women will be infected with one or more genital
HPV types during their lives, with a peak prevalence in
young sexually active individuals (7).
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The introduction of prophylactic vaccines represents
significant progress in the prevention of cervical cancer.
HPV prophylactic vaccines are using virus like particles
(VLPs). Currently licensed HPV vaccines, a bivalent
(Cervarix) and a quadrivalent HPV vaccine (Gardasil),
both protect against HPV types 16 and 18. In addition,
Gardasil protect against HPV 6 and 11, which cause
close to 90% of external genital wart cases (8). Longterm studies have shown that besides HPV 16 and 18,
acknowledged as the most frequently detected types in
ICC worldwide, HPV types 31, 33, 35, 45, 52, and 58 are
also frequently present. That was the starting point for
the development of a new recombinant 9-valent vaccine
by Merck, code named V503, that also uses VLPs. V503
contains 5 additional HPV types (31, 33, 45, 52, and 58)
to the four HPV types previously included in Gardasil,
and has successfully completed several studies. Phase III
studies are ongoing (9). However, in different parts of the
world some other oncogenic types play important roles in
the development of premalignant and malignant changes.
In order to estimate the effectiveness of a prospective
vaccination, prior assessment of the prevalence of HPV
genotypes and the heterogeneity of their distribution in the
population involved is needed. Region-specific differences
have already been detected (10,11). However, there are
still certain parts of the world lacking such important data,
Serbia being one of them (3). With this in mind, we have
undertaken the present study.
The goal of this study was to determine the presence
and age distribution of different oncogenic HPV types in a
population of women in the South Backa region and their
relationship to the results of Pap tests.

2.2. Cervical cytology
For cytological analysis, conventional Pap smears, obtained
with the use of cervical Ayre spatulas, were used to prepare
the slides in accordance with the standard screening
practice. Slides were evaluated at the Department of
Obstetrics and Gynecology, Clinical Center of Vojvodina,
Novi Sad, Serbia. A descriptive cytological classification
based on the Bethesda System 2001 was used (12).
2.3. Real-time PCR
HPV DNA detection and genotyping was performed by
real-time PCR at the Center of Virology, Institute of Public
Health of Vojvodina, Novi Sad, Serbia. Endocervical swabs
were collected in commercial transport media (Copan)
and stored at –20 °C until processed. HPV DNA isolation
protocol was carried out according to the manufacturer’s
original instructions (kit for the extraction of DNA, Sorb
A, Sacace, Italy). Twelve high risk HPV types (16, 18, 31,
33, 35, 39, 45, 51, 52, 56, 58, and 59) were determined in
the endocervical swabs with the HPV High Risk Typing
Real-TM kit (SACACE, Italy). An E7 gene was amplified
using the multiplex primers and four TaqMan probes. To
prove the high risk HPV, multiplex reaction was performed
in a volume of 13 µL. The process of amplification was
performed in 45 cycles under the following conditions: 15
min at 95 °C, 20 s at 95 °C, and 60 s at 60 °C.
2.4. Statistical analysis
The observed data were statistically processed by twoway ANOVA, for each individual type of HPV. Two
factors were examined: age and cytological diagnosis.
Analysis of variance and LSD tests were performed on
data transformed by arcsine transformation in order to
meet normal distribution of frequencies. Results were
considered significant if the probability was less than 0.05.

2. Materials and methods

3. Results
A total of 1087 women were involved in the study. The
age of the patients ranged between 18 and 65 years (with a
mean age of 35.9 years). The age-specific distribution was
as follows: <30 years (a mean age of 26.1), 30–39 years (a
mean age of 35.1), 40–49 years (a mean age of 45.1), and
≥50 years (a mean age of 55.5).
Following the collection of data on HPV DNA
genotypes, the samples were examined for the presence of
individual types. Overall, 50.5% of the women were HPV
positive. HPV DNA was positive in 36.4% of the women
with normal cervical cytology, in 66.7% of those with
ASCUS, in 82.3% of those with LSIL, and in 97.0% of those
with HSIL, as shown in Figure 1.
The results of the LSD test show that the proportion of
HPV positivity increased with the increase of cytological
abnormality, and decreased with age. The observed
differences were statistically significant among all
examined cytological diagnoses. However, the results of

2.1. Study design
Ethical approval for all study protocols was received from
the Institute of Public Health of Vojvodina, Novi Sad, Serbia.
The frequency of oncogenic HPV types was analyzed in a
sample of 1087 women (ages 18–65 years, with a mean age
of 35.9 years). The sample consisted of women attending
gynecological outpatient clinics for regular gynecologic
control at the Department of Obstetrics and Gynecology,
Clinical Center of Vojvodina, Novi Sad, Serbia. Both
women with normal and abnormal Pap smears were sent
for the virological diagnosis of HPV infection. The subjects
were grouped according to diagnosis. The study group
consisted of 307 women with atypical squamous cells of
undetermined significance (ASCUS), 97 women with low
grade squamous intraepithelial lesions (LSIL), 40 women
with high grade squamous intraepithelial lesions (HSIL),
and 643 women with normal cytology.
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Figure 1. Pap results and HPV positivity in the analyzed
group of women in South Backa region (NILM: negative for
intraepithelial lesion or malignancy; ASCUS: atypical squamous
cell of undetermined significance; LSIL: low-grade squamous
intraepithelial lesion; HSIL: high-grade squamous intraepithelial
lesion).

the LSD test showed that the smallest percentage of HPV
infected women was in the oldest age group (≥50, 56.4%),
while the differences among the other age groups (<30,
30–39, and 40–49) were not significant (75.8%, 65.7%, and
58.5% respectively), as shown in Figure 2.
Following the collection of data on HPV DNA
genotypes, the samples were examined for the presence of
individual types. In all samples positive for HPV DNA, the
distribution of HPV types was as follows: HPV 16 (37.3%),
HPV 31 (31.7%), HPV 51 (15.5%), HPV 52 (12.6%), HPV
18 (10.7%), HPV 56 (9.8%), HPV 45 (9.3%), HPV 33
(8.4%). HPV 58 (8.0%), HPV 59 (7.3%), HPV 39 (6.2%),
and HPV 35 (4.7%) (Figure 3). Multiple HPV infections
were found in 36.2%.
The significance of influence of controlled sources of
variation (age, cervical cytology, and the interaction of age
× cervical cytology) was examined by two-way ANOVA.
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Figure 2. Age distribution of HPV positivity among analyzed
women of South Backa region.
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Figure 3. Prevalence of 12 high risk HPV genotypes among
women in South Backa region.

Results of the F-test show that the presence of HPV types
18, 31, 33, 51, 58, and 59 was significantly influenced
by age, while the presence of HPV types 16 and 45 was
significantly influenced by cervical cytology as shown in
Table 1.
A wide spectrum of high risk HPV was found among
women with normal cytology and women with a low grade
cervical lesion rate (ASCUS and LSIL). The most prevalent
HPV types found were 16, 31, 51, 18, and 52. In the HSIL
group the most prevalent HPV types were 16 and 45. The
increase of the presence of these types clearly followed the
increase of the degree of cytological damage as shown in
Tables 2 and 3.
4. Discussion
This study presents results of the distribution of 12
oncogenic types of HPV among a nonvaccinated sample
of 1087 women (18–65 years old, with a mean age of
35.9) in the South Backa region of Serbia. The study was
conducted during an opportunistic screening program
that was conducted in Serbia. Overall, the HPV prevalence
(about 50.5%) is very high because women with both
normal and abnormal cytology were included. Although
HPV infection can cause cytological abnormalities, the
prevalence of HPV in women with normal cytological
Table 1. Results of ANOVA for the presence of types of HPV
in relation to the cytological diagnosis and age in the examined
sample of South Backa women.
HPV
type

F-test
Diagnosis

Age

Interaction

16

11.46

2.43

2.20*

18

0.76

4.75**

0.51

31

1.49

8.76**

1.58

33

2.42

3.76

1.56

35

2.31

1.07

0.42

39

1.34

1.38

0.80

45

10.87**

0.01

0.85

51

0.19

9.91

2.38*

52

1.32

1.76

56

1.50

58

3.61

59
Total

**

*

**

0.61

1.90

1.16
**

6.02

1.04

2.15

3.09

*

1.29

30.44**

1.96

*

1.13

*statistically significant; **highly statistically significant.
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Table 2. Results of the LSD test for the presence of individual
HPV types in relation to the age group.
HPV type/
cytological
diagnosis

NILM

ASCUS

LSIL

HSIL

16

9.66b

17.37c

25.77c

47.94a

18

1.41a

3.74a

4.03a

3.63a

31

9.23a

15.68a

13.01a

7.60a

33

0.80b

4.29a

1.87ab

1.83ab

35

0.34ab

1.84a

1.16ab

0.00ab

39

0.73a

1.59a

0.38a

4.30a

45

1.04b

0.74b

12.20a

18.37a

51

4.95a

5.77a

5.40a

3.63a

52

2.44a

5.21a

3.46a

0.81a

56

1.82a

4.24a

5.25a

7.94a

58

1.57b

2.46b

1.74b

0.00a

59

0.61a

3.59b

1.65ab

5.72b

Total

36.36d

66.70c

82.25b

96.96a

Labels of homogeneous groups: values with the same letter do
not differ significantly at the level α0.05.
Table 3. Results of the LSD test for the presence of individual
HPV types in relation to cytological diagnosis.
Age group/
HPV type

<30

31–40

41–50

>50

16

20.90ab

24.27a

18.66ab

11.91b

18

9.79a

2.36b

2.08b

0.34b

31

17.11b

18.99b

11.59

3.13a

33

4.38b

1.57ab

3.46b

0.34a

35

2.2a

0.51a

0.59a

0.28a

39

1.72a

1.98a

1.10a

0.40a

45

4.28a

3.24a

3.22a

2.43a

51

10.95a

8.21a

2.50b

1.64b

52

5.29a

4.88ab

2.79ab

0.97b

56

7.10a

2.35a

2.99a

3.34a

58

5.30a

2.29ab

0.66bc

0.07c

59

6.15a

0.93b

1.28b

1.51ab

Total

75.78a

65.69ab

58.46b

56.43b

Labels of homogeneous groups: values with the same letter do
not differ significantly at the level α0.05.
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findings is often high (13). Approximately 36.4% of
participants with normal cytology were HPV positive as
compared with 66.7% of the women with ASCUS, 82.3%
of those with low-grade SIL, and 97.0% of those with
high-grade SIL. Like many other countries, Serbia has no
obligatory reporting on HPV infection and comprehensive
data on the prevalence and incidence do not exist. The
available results come from several sporadic studies. By
using hybridization methods, the proportion of HPV
positivity among women from the South Backa District
(Vojvodina, Serbia) for the period of one decade was 51%
(14). In 2007, during the project Decena, the recorded
frequency of HPV infection was 16% by using hybrid
capture methods (15). Recently, using PCR amplification,
HPV prevalence was 19.1% in a study that was conducted
among 204 young women (16). Croatian HPV prevalence,
reported for a group of 205 women with normal cytology,
was 35.6% (CI: 29.1–42.6) (17). Our results were obtained
by a real-time PCR method and show an HPV DNA
prevalence of 50.5% in the analyzed women with different
cytological results. Evident variations in HPV rates can be
explained by differences in the age range, representation of
cytological diagnosis in the studied groups, the sensitivity
of the DNA assay used for the detection of HPV infection,
and the duration of the study.
The results of HPV positivity among different age
groups show that the highest percentage of infection was
present in the youngest women, namely 20–29 years of age
(75.8%), while in the oldest age group (50 years of age)
56.4% of the women were infected. Studies conducted
among women from 15 areas in four continents revealed
substantial variations in the shape of the age-specific
curves of HPV prevalence (18). In our study a decline of
HPV prevalence in the group above 50 years of age was
observed, while in a few studies from Asia, besides an
HPV peak in the youngest age group, a second peak was
observed in the older women. In contrast, in the rural areas
of Asia and in Nigeria the HPV prevalence was similar in
all age groups (19).
One of the goals of our study was the analysis of
individual HPV types in relation to age and cytology
results. The results showed that members of the alpha-9
HPV species, particularly HPV16 (found in 37.3%) and
HPV31 (found in 31.7%), were the most prevalent HPV
genotypes in our region. Additionally, 15.5% of the
infections were caused by the HPV51, a member of the
alpha-5 HPV species.
According to the results of many studies, HPV16 is
the most prevalent type worldwide, but its frequency
in geographically and ethnically diverse populations of
women worldwide is different (13). When we studied the
association of HPV16 with age and cytological diagnosis,
it was observed that this type of virus was widespread in all
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age groups, but its incidence significantly increased with
the severity of cytological lesions. The study of the natural
history of HPV16 in the development of anogenital
cancer conducted by Moscicki et al. proved that HPV
type 16 persists longer than the other types and is highly
carcinogenic; its risk of cervical intraepithelial neoplasia-3
(CIN3) is 40% at 5 years (20).
In the studied women of the South Backa region,
besides HPV 16, HPV type 31 is also abundant. HPV31
was represented in all age groups, but was more common in
younger women (17.1% in the 20–29 age group vs. 3.1% in
women older than 50 years). We did not find a statistically
significant influence of HPV31 on the cytological results.
According to a metaanalysis study conducted on five
continents, HPV31 is especially frequent in Europe (21).
HPV31 is considered the fourth most common HPV type
in squamous cervical carcinomas and in asymptomatic
patients worldwide (13). The remaining investigated
members of alpha-9 species (HPV 33, 35, 52, and 58)
were present in a low percentage in the studied region. In
our study HPV33 and HPV35 were more often found in
younger women and in ASCUS/LSIL cytology. However,
new data from the study of Sanjose et al. indicate that in
Europe HPV33 is responsible for 4% and HPV35 for 2% of
cervical carcinomas (11). HPV52 and HPV58 are typical
for regions of Asia, where both of them cause invasive
cervical carcinomas more frequently than in other world
regions (22). In our research, the frequencies of HPV52
and 58 were about 10%, with no statistically significant
influence of age and cytology on their variation.
The surprising fact is a conspicuously high prevalence
of HPV51 in the South Backa region. Research conducted
by Piana et al. confirmed the high prevalence of HPV51
infection among women with cervical dysplasia and
invasive disease in North Sardinia, Italy (23). This was
the first study pointing out such a strong association
between HPV51 and invasive cervical cancer. Recent
epidemiological studies show high HPV51 frequency in
several geographical areas of Europe, and among them is
the eastern Mediterranean. In a German population study
of young women, HPV51 was ranked second after HPV16
(24), and similar data were observed in the Netherlands
(25). Among Turkish women, HPV51 is ranked third (26).
In Bosnia and Herzegovina, Croatia, Czech Republic,
France, Greece, Italy, the Netherlands, Poland, Portugal,
and Spain HPV51 has been detected in only 1% of the
cases of cervical cancer (11). Although in our research it
was found that the prevalence of HPV51 decreased with
age, there were no significant differences in its prevalence
in relation to cytological abnormality groups. These data
suggest that the presence of this type could not be related
to the cancer incidence in our region. However, taking into
account the results of research in other regions (23,25),

the confirmation of this claim requires a study on a larger
number of subjects. Still, data on the prevalence of HPV51
are especially important since currently commercially
available vaccines and second generation nanovalent
prophylactic HPV vaccines do not protect against HPV51
(9,23).
Numerous studies conducted in the world show that
representatives of the alpha-7 species (HPV 18, 45, and
59) are responsible for 15% of invasive cervical cancers
and that they are strongly associated with adenocarcinoma
of the cervix (18). All members of this group were found
in a low percentage in our research. Similar to some
European studies, we found that in our region HPV18
was present at a lower percentage and its frequency was
five times lower than that of HPV16 (27). Furthermore,
if we consider the distribution of HVP genotypes in the
Balkan countries (Table 4), it could clearly be seen that
the frequency of HPV 18 ranks fourth or fifth in most
countries, enabling us to label it as a regional characteristic
(16,28–35). Although many studies clearly state that
the presence of HPV18 increases with the severity of
cytological lesions (18,21), we found it in 1.41%, 3.74%,
4.03%, and 3.63% of the NILM, ASCUS, LSIL, and HSIL
groups, respectively, with no statistical significance in the
differences among them. The low percentage of HPV18
in the HSIL group could be a consequence of the low
frequency of adenocarcinoma of the cervix in the analyzed
sample, taking into account that in our research women
with this diagnosis (adenocarcinoma) were not specifically
targeted. In order to reach reliable conclusions, we think
that research should be conducted on a larger scale.
In our study, HPV45 was detected rarely in women
with normal and ASCUS cytology. Furthermore, we
found that HPV45 behaved similarly to HPV16, and the
incidence of both of them significantly increased with the
severity of the cytological lesions. A retrospective crosssectional study conducted in 38 countries in Europe, North
America, Central and South America, Africa, Asia, and
Oceania, found that the mean age of patients with cervical
cancer is the lowest for HPV45 (46.8 years), followed by
HPV18 (48.2 years), and HPV16 (50.0 years) (36).
We observed that the prevalence of HPV59 decreased
with age, without a statistically significant influence on
cytology. The remaining member of the alpha-7 genus,
HPV39, was present in less than 5% of the studied women,
without a statistically significant influence of age and
cytology. The last researched HPV type was HPV56,
which belongs to the alpha-6 HPV species. According to
the analysis results of 3085 cervical carcinomas, HPV56
accounted for 1.2% of all cases worldwide (10). In our
study, the frequency of HPV56 was 9.8%, and we found
a mild statistically significant influence of age, without a
statistically significant influence on cytology.
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Table 4. HPV prevalence and types in the Balkan countries*.

Country

Overall HPV
prevalence

Prevalent HR-HPV types

HPV detection method

No. of tested
women

Age
range

Reference

Serbia

19.1%

16, 52, 33, 58

PCR/direct sequencing

204

19–31

16

Croatia

58.8%

16, 31, 33, 18, 52, 45, 58

Consensus primer/PCR

2136

12–75

28

Montenegro

-

16, 58, 31

Consensus primer/PCR

-

-

29

Bosnia and Herzegovina

-

16, 31, 51, 18

Multiplex real-time PCR

105

-

30

Macedonia

35.7%

16, 31, 53, 18

PCR-RFLP

7411

13–74

31

Romania

37.4%

16, 53, 51, 52, 18, 31

Linear array-Rosh

514

17–84

32

Bulgaria

38.8%

16, 56, 31, 33

-

1120

15–55

33

Albania

15.1%

16, 53, 31, 18

MY09/MY11 PCR

402

≥18

34

Greece

5.9%

16, 53, 31, 35, 51, 18

HybridCapture-2/ RFLP

4139

-

35

*Results vary with respect to the sample size, methods used, and criteria for sample selection. In order to obtain more reliable and plausible comparisons, close to uniform
study protocols are needed.

We observed that multiple HPV infections were
detected in 36.2% of all samples, and were more frequent
in women younger than 30 years. The overall prevalence
of multiple infections was higher than the one observed
by other authors (25.6%) from Serbia (16), and can be
attributed to differences in the samples selected for the
studies. While the patients analyzed in the work of Knezevic
et al. (16) consisted of women with normal Pap results
only, our sample included women with abnormal cytology
as well, meaning that those women already had some
problems and were referred to HPV testing subsequently.
The observation that multiple infections are more frequent
in younger women is consistent with the results of many
authors (20), and supports the fact that greater sexual
activity in younger women may be associated with the
transmission of multiple HPV types. Still, among younger
women HPV infections often have a transitory character.
In our study, a coinfection by HPV 31 and 51 was found
often. The question is whether multiple infections mean a
higher risk for cancer. One decade ago there was a view that
cervical neoplasia is the result of clonal expansion of a cell
infected with a single type of HPV (37). Some more recent
research investigated the importance of multiple infections
for carcinogenesis. Quint et al. examined the distribution of

multiple HPV infections in CIN lesions by the laser capture
microdissection PCR method and concluded that every
HPV type found in CIN is associated with a biologically
separate and independent CIN lesion (38).
The present work provides new data on the circulation
of oncogenic HPV genotypes and the frequency of multiple
infections among women in Vojvodina, Serbia. These data
suggest that a prophylactic vaccine against HPV 16 and 18
has the potential to prevent approximately half of the highgrade lesions. From the standpoint of designing a second
generation prophylactic HPV vaccines, it is important
to know the distribution of the most frequent oncogenic
human papillomavirus (HPV) in the population of certain
regions. Taking into account the variety of genotypes, future
therapeutic HPV vaccines would have greater potential
benefits if their design for treating HPV infections were
not restricted to HPV 16 and 18 only.
In the end, it is important to note that future wide-scale
HPV screening and research in Serbia is necessary, since
reliable data on specific HPV genotypes present in the
population would be valuable not only as a starting point
for the implementation of a vaccination program, but also
as a critical step in the algorithm of cancer diagnosis and
treatment of individual patients.
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